Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804383 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
A Phase 1 study, sponsored by Allyx Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT05804383 is a Phase 1 study that has completed, run by Allyx Therapeutics. The registered enrollment target is 51 participants.
The verdict
NCT05804383, a Phase 1 study, has completed, sponsored by Allyx Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Interventions
- DRUG Placebo
- DRUG BMS-984923
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05804383
The ClinicalTrials.gov registry entry for NCT05804383 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allyx Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05804383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05804383 about?
NCT05804383 is a clinical study titled "A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease". A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
What is the current status of trial NCT05804383?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2023-03-28. Estimated completion is 2025-10-15.
What interventions are being tested in trial NCT05804383?
The interventions under investigation include: Placebo (DRUG), BMS-984923 (DRUG).
Who is sponsoring clinical trial NCT05804383?
This trial is sponsored by Allyx Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.